Timothy Killeen, MD
Pulmonary Disease · Louisville, KYNPI 1730187790
Payments from drug & device makers
Across 151 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$676
- Inari Medical, Inc.$531
- GSK$420
- Insmed, Inc.$311
- Amgen$212
- plus $1K from 18 others
What the payments were for
- Food & beverage$5,471100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $2,171 |
| Boehringer Ingelheim | 38 | $676 |
| Inari Medical, Inc. | 4 | $531 |
| GSK | 24 | $420 |
| Insmed, Inc. | 10 | $311 |
| Amgen | 2 | $212 |
| Pulmonx Corporation | 2 | $212 |
| Abbott | 1 | $149 |
| Sanofi | 2 | $134 |
| Merck | 1 | $114 |
| Jazz Pharmaceuticals Inc. | 1 | $99 |
| Sunovion Pharmaceuticals Inc. | 6 | $91 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Mylan Specialty L.p. | 4 | $70 |
| Advanced Respiratory, Inc | 3 | $39 |
| Shire North American Group Inc | 2 | $35 |
| Getinge USA Sales, LLC | 1 | $20 |
| Pfizer | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| Ambu Inc. | 1 | $16 |
| Silk Road Medical, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$711
- FASENRA$603
- FLOWTRIEVER CATHETER, S$514
- CT THROMBECTOMY SYSTEM KIT$514
- BREZTRI$350
- Brinsupri$273
- DUPIXENT$240
- AIRSUPRA$232
- CentriMag$149
- Arikayce$137
- FARXIGA$135
- NUCALA$120
- CHARTIS CATHETER$116
- ZEPHYR DELIVERY CATHETER$116
- ZEPHYR ENDOBRONCHIAL VALVE$116
- PULMONX CHARTIS TABLET CONSOLE$116
- ZERBAXA$114
- Tavneos$113
How this compares
$5,482 in reported general payments places this provider in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $395,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 454 | $380,252 |
| Spiriva RespimatTiotropium Bromide | 153 | $115,612 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $76,660 |
| Breo ElliptaFluticasone/Vilanterol | 140 | $68,073 |
| SymbicortBudesonide/Formoterol Fumarate | 139 | $53,270 |
| Dupixent SyringeDupilumab | 15 | $53,205 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 79 | $43,642 |
| EliquisApixaban | 22 | $23,612 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $15,419 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $13,706 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $13,533 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 71 | $12,068 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $11,407 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 420 | $11,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $676 | $538,474232 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $420 | $514,223732 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,171 | $139,096242 claims |
| PfizerEliquis | $18 | $23,61222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$3.5M
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Lebnan SaadLouisville$105K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.